WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561823
CAS#: 22260-51-1
Description: Bromocriptine Mesylate is a dopamine agonist for the treatment of pituitary tumors, Parkinson's disease (PD), hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes.
Hodoodo Cat#: H561823
Name: Bromocriptine Mesylate
CAS#: 22260-51-1
Chemical Formula: C33H44BrN5O8S
Exact Mass: 0.00
Molecular Weight: 750.700
Elemental Analysis: C, 52.80; H, 5.91; Br, 10.64; N, 9.33; O, 17.05; S, 4.27
Synonym: Bromocriptine Mesylate; 2-Bromoergocryptine Mesylate;
IUPAC/Chemical Name: (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
InChi Key: NOJMTMIRQRDZMT-GSPXQYRGSA-N
InChi Code: InChI=1S/C32H40BrN5O5.CH4O3S/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18;1-5(2,3)4/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39);1H3,(H,2,3,4)/t18-,23-,24+,25+,31-,32+;/m1./s1
SMILES Code: O=C([C@H](C=C12)CN(C)[C@]2([H])CC3=C(Br)NC4=C3C1=CC=C4)N[C@@](O5)(C(C)C)C(N6[C@]5(O)[C@@](CCC7)([H])N7C([C@@H]6CC(C)C)=O)=O.CS(=O)(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 750.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015 Jan;99(1):87-106. doi: 10.1016/j.mcna.2014.08.012. Epub 2014 Oct 18. Review. PubMed PMID: 25456645.
2: Weiland CM, Hilaire ML. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus. Am Fam Physician. 2013 May 15;87(10):718-20. Review. PubMed PMID: 23939451.
3: Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother. 2010 Nov;44(11):1777-85. doi: 10.1345/aph.1P271. Epub 2010 Oct 26. Review. PubMed PMID: 20978217.
4: O'Keeffe ST. Restless legs syndrome. A review. Arch Intern Med. 1996 Feb 12;156(3):243-8. Review. PubMed PMID: 8572833.
5: Guay AT. Erectile dysfunction. Are you prepared to discuss it? Postgrad Med. 1995 Apr;97(4):127-30, 133-5, 139-40 passim. Review. PubMed PMID: 7716086.
6: Iffy L. Lethal cardiovascular complications in patients receiving bromocriptine for ablactation. Med Law. 1995;14(1-2):99-104. Review. PubMed PMID: 7666753.
7: Ahlskog JE. Treatment of Parkinson's disease. From theory to practice. Postgrad Med. 1994 Apr;95(5):52-4, 57-8, 61-4 passim. Review. PubMed PMID: 8153048.
8: Rampertaap MP. Neuroleptic malignant syndrome. South Med J. 1986 Mar;79(3):331-6. Review. PubMed PMID: 3513330.